Bowel Cancer ScreeningTET BETANCT07721740
Using Patient Navigation to Promote Bowel Screening in AAA Attendees.
A study testing Patient Navigation conversation in people with Bowel Cancer Screening, run by University of Surrey at 1 site in United Kingdom.
Trial summary
The goal of this single-arm, multi-centre feasibility study is to assess the efficacy, feasibility and acceptability of implementing patient navigation across Abdominal Aortic Aneurysm (AAA) screening services in England to increase uptake of bowel cancer screening. Read more about this study
- Who is it for?
- Ages 65 years and older, men onlyHealthy volunteers can take part
- Conditions the study is for
- Bowel Cancer Screening
- What is being tested?
- Patient Navigation conversation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,190 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 3 Aug 2026to 31 Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- Men only
- Healthy volunteers accepted
- Older adult
Who may be able to join
- Men aged 65 years and above
- Attending an AAA screening appointment
- Have not completed their most recent bowel screening
- Agree to discuss bowel screening further
Who cannot join
- Men aged <65years
- Those who do not attend their AAA screening appointment
- Have completed their most recent bowel screening
- Do not agree to discuss bowel screening further
- Those who received a positive AAA result in their appointment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site
University Hospitals of Leicester NHS Trust
Leicester
About this study
Official title: Testing the Efficacy, Feasibility, Acceptability and Cost-effectiveness of Patient Navigation to Promote Bowel Cancer Screening Participation Among Non-responders Attending Abdominal Aortic Aneurysm (AAA) Screening: A Multi-centre Pilot Study.
The goal of this single-arm, multi-centre feasibility study is to assess the efficacy, feasibility and acceptability of implementing patient navigation across Abdominal Aortic Aneurysm (AAA) screening services in England to increase uptake of bowel cancer screening. The main questions it aims to answer are:
- Do service users complete a bowel cancer screening within three months of receiving patient navigation?
- Do service deliverers consider patient navigation as feasible to implement in practice?
- Do service users consider patient navigation acceptable to receive during their AAA appointment? Participants will be asked to discuss bowel screening with AAA practitioners (patient navigation). Follow-up surveys and interviews will be conducted with those that delivered the intervention and with those that received it.
Read the detailed description
Bowel cancer is a leading cause of cancer-related mortality in England. Biennial Faecal Immunochemical Test (FIT) screening can reduce bowel cancer-related deaths by detecting cases before symptoms develop. However, uptake remains suboptimal, particularly among men. Evidence from a single-centre study in Scotland suggests that a brief intervention, akin to patient navigation, delivered to men attending routine abdominal aortic aneurysm (AAA) screening appointments, can facilitate participation.
The overarching aim of this study is to evaluate the efficacy, feasibility, acceptability and cost-effectiveness of implementing patient navigation intervention across AAA screening services in England.
This study will be a single-arm, multi-centre feasibility study that will be conducted across five AAA screening centres in England, i.e. Leicester, Birmingham and Black Country, London, West Yorkshire, and Somerset and North Devon. Over a three-month period (August-November 2026), AAA screening practitioners will deliver patient navigation to a sample of approximately 4190 men, aged 65+ years, who attend AAA screening and self-report as bowel screening non-responders.
The primary outcome of the study is completion of a FIT kit within three months of the AAA appointment. Secondary outcomes include the feasibility, acceptability and cost-effectiveness of the intervention.
The study comprises three Work Packages:
Work Package 1 will be the single-arm, multi-centre feasibility study. The outcome will be the completion of a bowel cancer screening kit, providing preliminary evidence of efficacy.
Work Package 2 will evaluate feasibility from the service provider perspective, using surveys (Workstream 2a) and interviews (Workstream 2b) with AAA service providers.
Work Package 3 will assess acceptability from the service user perspective, using surveys (Workstream 3a) and interviews (Workstream 3b) with those who received the intervention during the study period.
The findings will be used to inform an implementation toolkit as part of a national strategy to improve the uptake of bowel screening.
- Conditions
- Bowel Cancer Screening
- Being tested
- Patient Navigation conversation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient Navigation conversationOther
Brief 1.5-2 minute conversation to discuss barriers and solutions to why have not completed most recent bowel screening. Offer of third party request or information to contact screening service.
| Study group | Role | What they receive |
|---|---|---|
| Patient Navigation | Other | Eligibility: Men who have a negative AAA result, indicate that they have not completed their most recent bowel screening and are happy to discuss this further.
Intervention: A 2 minute Patient Navigation intervention (discussion regarding barriers to completing bowel cancer screening) Receives: Other: Patient Navigation conversation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of FIT test completed
Completion of FIT test
Measured: Completion within 3 months of patient navigation intervention
Secondary outcomes (4)
Feasibility of delivering patient navigation (survey)
Survey with those who delivered patient navigation. Survey contains 7 items: 2 demographic questions, 2 items on a 3-point Likert scale (with option to provide further detail in open text), 2 open text responses, and one dichotomous item (Yes/No). The Likert scales are scored where 1 is low and 3 is high.
Measured: 0-5 months post patient navigation delivery
Feasibility of delivering patient navigation (Interviews)
Semi-structured interviews with those who delivered patient navigation
Measured: 0-5 months post patient navigation delivery
Acceptability of receiving patient navigation (Survey)
Survey with service users who received patient navigation. Survey contains 12 items: 4 demographic questions, 5 items on a 5-point Likert scale, and 3 open text responses. The Likert scales are scored where 1 is high and 5 is low.
Measured: 0-5 months post patient navigation
Acceptability of receiving patient navigation (Interviews)
Semi-structured interviews with service users who received patient navigation
Measured: 0-5 months post patient navigation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2026
- Study start3 Aug 2026 (estimated)
- Primary completion1 Mar 2027 (estimated)
- Study completion31 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bowel Cancer ScreeningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 4,190 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Surrey
- Sponsor type
- University, hospital or other
- Collaborators
- Cancer Research UK, NHS England
- Responsible party
- Sponsor
- Investigators
- Robert Kerrison, PhD, Principal investigator, University of Surrey
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07721740
- Sponsor's protocol ID
- SPON 2026-06
- Acronym
- TET BETA
- Status last verified
- Jun 2026
- First submitted
- 3 Jul 2026
- Last updated
- 23 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Testing the Efficacy, Feasibility, Acceptability and Cost-effectiveness of Patient Navigation to Promote Bowel Cancer Screening Participation Among Non-responders Attending Abdominal Aortic Aneurysm (AAA) Screening: A Multi-centre Pilot Study.
- ClinicalTrials.gov ID
- NCT07721740
- Acronym / sponsor ID
- TET BETA / SPON 2026-06
- Conditions
- Bowel Cancer Screening
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 4,190 participants (estimated)
- Lead sponsor
- University of SurreyUniversity, hospital or other
- Collaborators
- Cancer Research UK, NHS England
- Study start
- 3 Aug 2026 (estimated)
- Primary completion
- 1 Mar 2027 (estimated)
- Study completion
- 31 Jul 2027 (estimated)
- First posted
- 23 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this single-arm, multi-centre feasibility study is to assess the efficacy, feasibility and acceptability of implementing patient navigation across Abdominal Aortic Aneurysm (AAA) screening services in England to increase uptake of bowel cancer screening. The main questions it aims to answer are:
- Do service users complete a bowel cancer screening within three months of receiving patient navigation?
- Do service deliverers consider patient navigation as feasible to implement in practice?
- Do service users consider patient navigation acceptable to receive during their AAA appointment? Participants will be asked to discuss bowel screening with AAA practitioners (patient navigation). Follow-up surveys and interviews will be conducted with those that delivered the intervention and with those that received it.
Detailed description
Bowel cancer is a leading cause of cancer-related mortality in England. Biennial Faecal Immunochemical Test (FIT) screening can reduce bowel cancer-related deaths by detecting cases before symptoms develop. However, uptake remains suboptimal, particularly among men. Evidence from a single-centre study in Scotland suggests that a brief intervention, akin to patient navigation, delivered to men attending routine abdominal aortic aneurysm (AAA) screening appointments, can facilitate participation.
The overarching aim of this study is to evaluate the efficacy, feasibility, acceptability and cost-effectiveness of implementing patient navigation intervention across AAA screening services in England.
This study will be a single-arm, multi-centre feasibility study that will be conducted across five AAA screening centres in England, i.e. Leicester, Birmingham and Black Country, London, West Yorkshire, and Somerset and North Devon. Over a three-month period (August-November 2026), AAA screening practitioners will deliver patient navigation to a sample of approximately 4190 men, aged 65+ years, who attend AAA screening and self-report as bowel screening non-responders.
The primary outcome of the study is completion of a FIT kit within three months of the AAA appointment. Secondary outcomes include the feasibility, acceptability and cost-effectiveness of the intervention.
The study comprises three Work Packages:
Work Package 1 will be the single-arm, multi-centre feasibility study. The outcome will be the completion of a bowel cancer screening kit, providing preliminary evidence of efficacy.
Work Package 2 will evaluate feasibility from the service provider perspective, using surveys (Workstream 2a) and interviews (Workstream 2b) with AAA service providers.
Work Package 3 will assess acceptability from the service user perspective, using surveys (Workstream 3a) and interviews (Workstream 3b) with those who received the intervention during the study period.
The findings will be used to inform an implementation toolkit as part of a national strategy to improve the uptake of bowel screening.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patient Navigation | Other | Other: Patient Navigation conversationEligibility: Men who have a negative AAA result, indicate that they have not completed their most recent bowel screening and are happy to discuss this further. Intervention: A 2 minute Patient Navigation intervention (discussion regarding barriers to completing bowel cancer screening) |
Who may qualify
- Ages
- 65 years and older
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Older adult
Key inclusion criteria (4 listed)
- Men aged 65 years and above
- Attending an AAA screening appointment
- Have not completed their most recent bowel screening
- Agree to discuss bowel screening further
Key exclusion criteria (5 listed)
- Men aged <65years
- Those who do not attend their AAA screening appointment
- Have completed their most recent bowel screening
- Do not agree to discuss bowel screening further
- Those who received a positive AAA result in their appointment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patient Navigation conversationBrief 1.5-2 minute conversation to discuss barriers and solutions to why have not completed most recent bowel screening. Offer of third party request or information to contact screening service. | Other | Patient Navigation |
Primary outcome
Number of FIT test completed
Time frame: Completion within 3 months of patient navigation intervention
Completion of FIT test
4 secondary outcomes
Feasibility of delivering patient navigation (survey)
Time frame: 0-5 months post patient navigation delivery
Feasibility of delivering patient navigation (Interviews)
Time frame: 0-5 months post patient navigation delivery
Acceptability of receiving patient navigation (Survey)
Time frame: 0-5 months post patient navigation
Acceptability of receiving patient navigation (Interviews)
Time frame: 0-5 months post patient navigation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Bowel Cancer Screening
Active, not recruiting
Guardant Shield Colorectal Cancer Screening
Colorectal Cancer
Active, not recruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Not yet recruiting
The PharmFIT Study
Colorectal Cancer
Not yet recruiting
Life Expectancy-informed Colorectal Cancer Screening
Colorectal Cancer Control and Prevention
Enrolling by invitationObservational study
Protein Signature Based Screening of Colorectal Adenomas and Cancer
Colorectal Cancer, Colorectal Adenoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Robert Kerrison, PhD principal investigator
University of Surrey
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Patient Navigation conversation in people with Bowel Cancer Screening, run by University of Surrey at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Elizabeth Bailey (+441483 300800, assurance@surrey.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of FIT test completed (time frame: Completion within 3 months of patient navigation intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2026.